Everyone Is Talking About Eli Lilly. Is It a Good Long-Term Option?
Eli Lilly (NYSE: LLY) has grabbed the attention of investors and the general public in recent times. That's because two of its drugs are taking the billion-dollar weight loss market by storm. Regulators first approved tirzepatide under the commercial name Mounjaro for type 2 diabetes -- but doctors also have been prescribing it off-label for weight loss. Then, late last year, regulators gave the nod to the molecule as Zepbound specifically for chronic weight management.
Mounjaro and Lilly's portfolio of drugs across treatment areas helped the company report a double-digit increase in sales in the most recent quarter. And investors have cheered Lilly's progress, lifting the shares more than 50% last year. That made Lilly a winning bet for short-term investors -- but is this pharma giant a good long-term option? Let's find out.
Image source: Getty Images.
Source Fool.com
